Several degenerative disorders of the central nervous system, including Parkinson’s
disease (PD), are related to the pathological aggregation of proteins. Antibodies
against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed
as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was
used as the epitope to construct magnetic molecularly imprinted composite nanoparticles
(MMIPs). These composite nanoparticles were characterized by dynamic light scattering
(DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry
(ITC), Brunauer–Emmett–Teller (BET) analysis, and superconducting quantum interference
device (SQUID) analysis. Finally, the viability of brain endothelial cells that were
treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated
HEK293T cells from the in vitro model system was demonstrated for the therapeutic
application of MMIPs.
